Literature DB >> 2194429

T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome.

H P Hartung1, K V Toyka.   

Abstract

Evidence implicating cellular immune responses in the pathogenesis of experimental autoimmune neuritis (EAN) and Guillain-Barré syndrome (GBS) is reviewed. In EAN the decisive role of T-lymphocytes in the initiation of immune-mediated nerve damage has been firmly established by adoptive transfer experiments. Macrophages but not Schwann cells express major histocompatibility complex class II gene products in situ and hence may function as antigen presenters. Macrophages are crucial in the amplification and effector phase and damage the myelin sheath by phagocytic attack and release of inflammatory mediators such as toxic oxygen radicals, arachidonic acid metabolites, complement, or hydrolases. Macrophage activation in EAN is achieved by interferon-gamma. Attempts to detect specific sensitization of T-lymphocytes to nerve antigens in patients with GBS have so far been unsuccessful. However, circulating activated T cells can be found in patients with GBS, as evidenced by augmented expression of HLA-DR antigen, the transferrin receptor, and the interleukin-2 receptor on the surface of peripheral blood T cells, and by increased serum concentrations of interleukin-2 and the soluble interleukin-2 receptor. In addition, we present data indicating macrophage activation in GBS.

Entities:  

Mesh:

Year:  1990        PMID: 2194429     DOI: 10.1002/ana.410270716

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

Review 1.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

4.  Suppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6.

Authors:  G Deretzi; S Pelidou; L Zou; C Quiding; E Mix; M Levi; B Wahren; J Zhu
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

5.  P2-peptide induced experimental allergic neuritis: a model to study axonal degeneration.

Authors:  A F Hahn; T E Feasby; L Wilkie; D Lovgren
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies.

Authors:  M Rentzos; C Nikolaou; A Rombos; K Voumvourakis; I Segditsa; C Papageorgiou
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

7.  The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid.

Authors:  H Brinkmeier; K H Wollinsky; P J Hülser; M J Seewald; H H Mehrkens; H H Kornhuber; R Rüdel
Journal:  Pflugers Arch       Date:  1992-09       Impact factor: 3.657

8.  Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell lines.

Authors:  H C Powell; R R Myers; A P Mizisin; T Olee; S W Brostoff
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Dorsal root ganglia cocultured with macrophages: an in vitro model to study experimental demyelination.

Authors:  W Brück; Y Brück; U Diederich; R L Friede
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN.

Authors:  S Jung; H J Schluesener; B Schmidt; A Fontana; K V Toyka; H P Hartung
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.